PDCD1 and hepatocellular carcinoma: Similarly, the RATIONALE-301 study, which compared the anti-PD-1 antibody tislelizumab with sorafenib in the frontline setting for advanced HCC in a predominantly Asian population, showed non-inferiority but not superiority in OS (15.9 vs. 14.1 months, HR 0.85, 95% CI 0.71–1.02) [6].